Millendo Therapeutics Overview
Latest ROE for Millendo Therapeutics: 3713.03% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow3713.03%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for MLND is 3713.03%. That is above the Healthcare sector average of -75.59%. Investors often review this figure alongside Millendo Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, MLND currently prints 3713.03% for ROE, while the sector average sits near -75.59%. That is roughly 5011.9% above the sector mean. Large gaps often invite a closer look at Millendo Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Millendo Therapeutics converts resources into returns. At 3713.03%, MLND may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting MLND's ROE (3713.03%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Millendo Therapeutics's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
